Performance-enhanced mesenchymal stem cells via intracellular delivery of steroids

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Ankrum, James A ^a,b   Dastidar, Riddhi G ^a   Ong, Joon Faii ^a   Levy, Oren ^a   Karp, Jeffrey M ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BUDESONIDE; DEXAMETHASONE; GAMMA INTERFERON; GLUCOCORTICOID; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DR ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; NANOPARTICLE; SMALL INTERFERING RNA;

ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL PROLIFERATION; HUMAN; MESENCHYMAL STROMA CELL; METABOLISM; RNA INTERFERENCE;

ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CELL PROLIFERATION; CELLS, CULTURED; DEXAMETHASONE; GLUCOCORTICOIDS; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-C ANTIGENS; HLA-DR ANTIGENS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; MESENCHYMAL STROMAL CELLS; NANOPARTICLES; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84898482138     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04645     Document Type: Article

References (48)

1. Ankrum, J.&Karp, J. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med 16, 203-209 (2010).
2. Bahr von, L. et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol. Blood Marrow Transplant. 18, 557-564 (2012).
3. Le Blanc, K. et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371, 1579-1586 (2008). (Pubitemid 351626841)
4. Mills, C. R. Osiris Therapeutics Announces Preliminary Results for PRochymal Phase III GvHD Trials. Osiris Press Release (2009)at ,http://files.shareholder. com/downloads/OSIR/2468414599x0x317779/7677da46-286a- 47c4-865d-36c148119a1a/OSIRNews200998General.pdf..
5. Galipeau, J. The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graftversus-host disease represent a death knell or a bump in the road? Cytotherapy 15, 2-8 (2013).
6. Melief, S. M., Zwaginga, J. J., Fibbe, W. E. & Roelofs, H. Adipose Tissue-Derived Multipotent Stromal Cells Have a Higher Immunomodulatory Capacity Than Their Bone Marrow-Derived Counterparts. Stem Cells Translational Medicine doi:10.5966/sctm.2012-0184 (2013).
7. François, M., Romieu-Mourez, R., Li, M. & Galipeau, J. HumanMSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 20, 187-195 (2012).
8. Zhukareva, V., Obrocka, M., Houle, J. D., Fischer, I. & Neuhuber, B. Secretion profile of human bone marrow stromal cells: donor variability and response to inflammatory stimuli. Cytokine 50, 317-321 (2010).
9. Prockop, D. J. Two Negative Feedback Loops Place Mesenchymal Stem/Stromal Cells (MSCs) at the Center of Early Regulators of Inflammation. Stem Cell doi:10.1002/stem.1400 (2013).
10. Lee, R. H. et al. Intravenous hMSCs Improve Myocardial Infarction in Mice because Cells Embolized in Lung Are Activated to Secrete the Anti-inflammatory Protein TSG-6. Cell Stem Cell 5, 54-63 (2009).
11. Kidd, S. et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cell 27, 2614-2623 (2009).
12. Strioga, M., Viswanathan, S., Darinskas, A., Slaby, O. & Michalek, J. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev 21, 2724-2752 (2012).
13. Ren, G. et al. Species Variation in the Mechanisms of Mesenchymal Stem Cell-Mediated Immunosuppression. Stem Cell 27, 1954-1962 (2009).
14. Nauta, A. J. & Fibbe, W. E. Immunomodulatory properties of mesenchymal stromal cells. Blood 110, 3499-3506 (2007). (Pubitemid 350159613)
15. Bubnoff, D. & Bieber, T. The indoleamine 2,3-dioxygenase (IDO) pathway controls allergy. Allergy 67, 718-725 (2012).
16. Meisel, R. et al. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia 25, 648-654 (2011).
17. Munn, D. H. & Mellor, A. L. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends in Immunology 34, 137-143 (2013).
18. Munn, D. H. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191-1193 (1998). (Pubitemid 28406294)
19. Prendergast, G. C.,Metz, R.&Muller, A. J. Towards a genetic definition of cancerassociated inflammation: role of the IDO pathway. Am. J. Pathol. 176, 2082-2087 (2010).
20. Munn, D. H. et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22, 633-642 (2005). (Pubitemid 40719198)
21. Terness, P. et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196, 447-457 (2002).
22. Fallarino, F. et al. IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J Immunol 183, 6303-6312 (2009).
23. Grohmann, U. et al. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med 13, 579-586 (2007). (Pubitemid 46828479)
24. Puccetti, P. & Grohmann, U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol 7, 817-823 (2007). (Pubitemid 47480306)
25. Türck, J., Oberdörfer, C., Vogel, T., Mackenzie, C. R. & Däubener, W. Enhancement of antimicrobial effects by glucocorticoids. Med. Microbiol. Immunol. 194, 47-53 (2005).
26. Kebriaei, P. et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol. Blood Marrow Transplant. 15, 804-811 (2009).
27. Fakih, El, R., Obi, G. A., Scholoff, A., Carrum, G. & Kamble, R. T. Systemic effects of oral budesonide in hematopoietic transplant: implications of drug interaction with azoles. Bone Marrow Transplant 47, 1370-1371 (2012).
28. Webster, J. & Cidlowski, J. Mechanisms of Glucocorticoid-receptor- mediated Repression of Gene Expression. Trends Endocrinol. Metab. 10, 396-402 (1999).
29. Hammer, S. et al. Glucocorticoids mediate differential anti-apoptotic effects in human fibroblasts and keratinocytes via sphingosine-1-phosphate formation. J. Cell. Biochem. 91, 840-851 (2004).
30. Spurzem, J. R., Sacco, O., Rossi, G. A., Beckmann, J. D. & Rennard, S. I. Regulation of major histocompatibility complex class II gene expression on bovine bronchial epithelial cells. J. Lab. Clin. Med. 120, 94-102 (1992).
31. Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E. & Ringdén, O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31, 890-896 (2003). (Pubitemid 37211373)
32. Cheon, H. & Stark, G. R. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proceedings of the National Academy of Sciences 106, 9373-9378 (2009).
33. Wu, Y. et al. Up-regulation and Sustained Activation of Stat1 Are Essential for Interferon-(IFN-)-induced Dual Oxidase 2 (Duox2) and Dual Oxidase A2 (DuoxA2) Expression in Human Pancreatic Cancer Cell Lines. J Biol Chem 286, 12245-12256 (2011).
34. Morrow, A. N., Schmeisser, H., Tsuno, T. & Zoon, K. C. A Novel Role for IFNStimulated Gene Factor 3II in IFN-Signaling and Induction of Antiviral Activity in Human Cells. J Immunol 186, 1685-1693 (2011).
35. Lützner, N., Kalbacher, H., Krones-Herzig, A. & Rösl, F. FOXO3 Is a Glucocorticoid Receptor Target and Regulates LKB1 and Its Own Expression Based on Cellular AMP Levels via a Positive Autoregulatory Loop. PLoS ONE 7, e42166 (2012).
36. Toogood, J. H. Side effects of inhaled corticosteroids. J. Allergy Clin. Immunol. 102, 705-713 (1998). (Pubitemid 28543517)
37. Buchman, A. L. Side Effects of Corticosteroid Therapy. Journal of Clinical Gastroenterology 33, 289 (2001).
38. Ankrum, J. et al. Engineering cells with intracellular agent-loaded microparticles to control cell phenotype. Nat Protoc 9, 233-245 (2014).
39. Sarkar, D., Ankrum, J., Teo, G. S. L., Carman, C. V. & Karp, J. M. Cellular and extracellular programming of cell fate through engineered intracrine-, paracrine-, and endocrine-like mechanisms. Biomaterials 32, 3053-3061 (2011).
40. Xu, C. et al. Tracking Mesenchymal Stem Cells with Iron Oxide Nanoparticle Loaded Poly(lactide-co-glycolide) Microparticles. Nano Lett 12, 4131-4139 (2012).
41. Distelhorst, C. W. Recent insights into the mechanism of glucocorticosteroidinduced apoptosis. Cell Death Differ 9, 6-19 (2002). (Pubitemid 34071989)
42. la Garza-Rodea, de, A, S. et al. Exploitation of herpesvirus immune evasion strategies to modify the immunogenicity of human mesenchymal stem cell transplants. PLoS ONE 6, e14493 (2011).
43. Soland, M. A. et al. Modulation of Human Mesenchymal Stem Cell Immunogenicity through Forced Expression of Human Cytomegalovirus US Proteins. PLoS ONE 7, e36163 (2012).
44. 3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells. Nature Immunology 10, 504-513 (2009).
45. 3: A master switch for regulating tolerance and immunity in dendritic cells. oncoimmunology 1, 252-254 (2012).
46. Watkins, S. K. et al. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J. Clin. Invest. 121, 1361-1372 (2011).
47. Liu, H., Liu, L., Fletcher, B. S. & Visner, G. A. Sleeping Beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis. The FASEB Journal 20, 2384-2386 (2006).
48. Ankrum, J., Ong, J.F. & Karp, J. M. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 32(3), 252-260 (2006).